###### Strengths and limitations of this study

-   This is the first systematic review and meta-analysis to evaluate the association between vitamin D binding protein (*DBP*) polymorphisms and type 2 diabetes mellitus (T2DM).

-   All the articles included in this manuscript must confirm that all controls were in the Hardy-Weinberg equilibrium. Heterogeneity test, meta-regression and sensitivity analysis were also conducted.

-   It still needs to be demonstrated that *DBP* polymorphisms were associated with T2DM in other places such as Africa and South America.

Introduction {#s1}
============

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder caused by the interaction of multiple genetic and environmental factors, and the suggested overall genetic contribution is around 50--70%; until now, more than 60 genes have been reported to relate to T2DM, and these genes always contain polymorphisms that modify their function.[@R1]

Vitamin D binding protein (*DBP*), also known as a group-specific component protein (*Gc*), is a multifunctional serum glycoprotein.[@R4] As a major plasma carrier protein of vitamin D sterols, *DBP* is essential for the intracellular metabolism of vitamin D.[@R5] So variations in *DBP* might influence the amount and activity of vitamin D, and then alter insulin secretion, β-cell dysfunction and glucose metabolism.[@R6]

DBP gene spans 35 kilobase pairs and contains 13 exons and 12 introns, and maps to the long arm of chromosome 4 (4q12--q13).[@R5] [@R9] There are two major polymorphisms in DBP which were studied. A nucleotide exchange (*GAT* to *GAG*) in position 416 contributes to an Asp to Glu exchange. Additionally, the *ACG* to *AAG* in position 420 changes Thr to Lys.[@R10] A few previous studies have been carried out to access the association between *DBP* polymorphisms and risk of T2DM in different populations; however, the results are inconsistent and inconclusive.[@R11] Therefore, it remains uncertain if DBP polymorphisms are really associated with an increased risk of T2DM. The purpose of this study was to assess the association of DBP polymorphisms with T2DM by conducting a systematic review and meta-analysis from individual data sets of all relevant studies published to date.

Materials and methods {#s2}
=====================

Literature and search strategy {#s2a}
------------------------------

The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.[@R17] A computerised literature search was conducted using the Cochrane, Pubmed, ISI, CNKI (Chinese) and Wanfang (Chinese) databases for relevant articles published in English and Chinese before the end of March 2014. The search terms were as follows: "vitamin D binding protein or group-specific component protein (DBP or Gc)" and "polymorphism or variant" and "type 2 diabetes mellitus (T2DM)". In addition, the reference lists of original and review articles were also researched to identify any additional relevant articles using the previous databases.

The included studies must meet the following criteria: (1) the design had to be a case-control or correlation study; (2) there is a description of DBP genotype frequencies in cases and controls provided; (3) the study evaluated the association between DBP polymorphisms and T2DM; (4) there were sufficient data for estimating an OR with 95% CI. In all the studies, genomic DNA from people was extracted from blood and DBP status was determined by analysis of the gene through PCR single strand conformation polymorphism (PCR-SSCP), PCR restriction fragment length polymorphisms (PCR-RFLP), PCR-based denaturing high-performance liquid chromatography (DHPLC), conforming two-pair primers (CTPP) or biochip.

Data extraction {#s2b}
---------------

Data were extracted and entered into a database by two investigators (GW and YL) independently. For conflicting evaluations, an agreement was reached following a discussion. The data extracted were as follows: the surname of the first author, journal, date of publication, country of origin, ethnicity, study design, characteristics of cases and controls, matching variables, mean age of the case group, number of cases and controls, genotyping method, genotype distribution of cases and controls, quality control for genotyping assay and the Hardy-Weinberg equilibrium (HWE). In addition, the studies were appraised by the publication influence factor, restriction of control, data completion and so on.

Statistical analysis {#s2c}
--------------------

OR with 95% CI was calculated to estimate the relationship between the DBP polymorphisms and T2DM. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of studies on three broad perspectives.[@R18] A 'star system' (out of 9 stars) was used to describe the quality of studies. A random-effects model would first be used to estimate the pooled OR value, and then a fixed-effects model would be applied when p\>0.10 in the heterogeneity analysis. We assessed heterogeneity in effect estimates using Ι^2^, p value for heterogeneity (Ph). If there is a significant heterogeneity (Ph≤0.1 or Ι^2^\>50%) among studies, we will explore the source of heterogeneity by meta-regression and perform sensitivity analysis. Sensitivity analysis was performed by removing the lowest quality of study which is inconsistent with HWE to assess the stability of the results. For each polymorphism site, four genetic models were used (using codon 416 as an example): allele comparison (Glu vs Asp), codominant model (Glu/Glu vs Asp/Asp, Glu/Asp vs Asp/Asp), dominant model (Glu/Asp+Glu/Glu vs Asp/Asp). Studies were stratified according to source of cases, ethnicity and source of controls for exploration of heterogeneity. All analyses were performed by the STATA software package, V.11.0 (STATACorp., College Station, Texas, USA).

Results {#s3}
=======

Characteristics of included studies {#s3a}
-----------------------------------

The detailed selection process is shown in [figure 1](#BMJOPEN2014005617F1){ref-type="fig"}. In total, 92 studies were identified using five electronic databases and a manual search. Fourteen articles were excluded for duplicate publication. After reading the title and abstract, fifty-nine reports were excluded (48 articles were not relevant to DBP polymorphism, 5 articles were not relevant to T2DM, and 6 articles were review articles). After the full-text evaluation, 13 articles were excluded with reasons for no available data (n=6), duplicate publications (n=4), no case-control studies (n=2), and no human study (n=1). Finally, six studies (4 in English and 2 in Chinese) were included in this meta-analysis.

![Flow diagram for literature inclusion and exclusion (DBP, vitamin D binding protein; T2DM, type 2 diabetes mellitus).](bmjopen2014005617f01){#BMJOPEN2014005617F1}

The characteristics of these studies are listed in [table 1](#BMJOPEN2014005617TB1){ref-type="table"}. There were three studies based on the Asian population and three studies conducted on the Caucasian population. These six articles were all about codon 416 and codon 420, and included 1191 cases and 882 controls. The detection methods of genotype were all PCR-RFLP. Except for one study,[@R11] the genotype distributions in the controls of all studies were inconsistent with HWE. The quality of studies was described by the number of stars.

###### 

The basic characteristics of the included studies

  First author (year)   Country (ethnicity)   Participants   Cases source   Cases age (mean±SD, year)   HWE (p value\*)            
  --------------------- --------------------- -------------- -------------- --------------------------- ----------------- -------- -------
  Ye WZ (2001)          France (Caucasian)    237            143            Hospital                    63.00±11.00       0.730    0.710
  Klupa T (1999)        America (Caucasian)   215            163            Population                  62.30±5.40        0.841    0.811
  Malecki MT (2002)     Poland (Caucasian)    231            162            Population                  57.10±11.40       0.148    0.081
  Shao XJ (2012)        China (Asian)         105            105            Hospital                    60.67±11.69       0.223    1.000
  Ren W (2003)          China (Asian)         201            110            Population                  52.65±12.07       0.372    0.846
  Hirai M (1998)        Japan (Asian)         202            199            Population                  NR                0.0001   0.025

\*p Value for the HWE in the control group.

HWE, Hardy-Weinberg equilibrium; NR, not reported.

Quantitative data synthesis {#s3b}
---------------------------

[Figures 2](#BMJOPEN2014005617F2){ref-type="fig"} and [3](#BMJOPEN2014005617F3){ref-type="fig"} summarise the ORs with corresponding 95% CIs for the association between codon 416 and codon 420 polymorphisms in the DBP and the risk for T2DM under all genetic models. Overall, there was no evidence of an association between codon 416 and codon 420 polymorphisms and the risk of T2DM when all the eligible publications were pooled into the meta-analysis. In the subgroup analysis by ethnicity, a significant association between the codon 420 polymorphism and the risk of T2DM was found in Asians (allele Lys vs Thr: OR (95% CI) 1.49 (1.19 to 1.85), genotype Lys/Thr versus Thr/Thr: OR (95% CI) 1.80 (1.36 to 2.38), and Lys/Thr+Lys/Lys versus Thr/Thr: OR (95% CI) 1.81 (1.37 to 2.39), respectively). For codon 416, a similar association was also detected in Asians (Glu/Asp+ Glu/Glu vs Asp/Asp: OR (95% CI) 1.36 (1.04 to 1.78). For Caucasians, no significant associations between codon 416 and codon 420 polymorphisms and T2DM were observed under all the four genetic models. The results are presented in [tables 3](#BMJOPEN2014005617TB3){ref-type="table"} and [4](#BMJOPEN2014005617TB4){ref-type="table"}.

###### 

Results of meta-regression (p value)

  Group                        Case source   Ethnic   Control source   
  ---------------------------- ------------- -------- ---------------- -------
  Codon 416                    Glu vs Asp    0.565    0.217            0.553
  Glu/Glu vs Asp/Asp           0.468         0.522    0.725            
  Glu/Asp vs Asp/Asp           0.911         0.087    0.254            
  Glu/Asp+Glu/Glu vs Asp/Asp   0.839         0.090    0.286            
  Codon 420                    Lys vs Thr    0.316    0.051            0.600
  Lys/Lys vs Thr/Thr           0.430         0.279    0.316            
  Lys/Thr vs Thr/Thr           0.352         0.045    0.632            
  Lys/Thr+Lys/Lys vs Thr/Thr   0.344         0.037    0.627            

###### 

Pooled ORs and 95% CIs of overall and subgroup meta-analysis, heterogeneity test and sensitivity analysis in the codon 416 polymorphism

  Genetic model                Meta-analysis         Sensitivity analysis                                               
  ---------------------------- --------------------- ---------------------- -------------- --------------------- ------ -------------
  Codon 416 (overall)                                                                                                   
  Glu vs Asp                   1.10 (0.97 to 1.26)   0.35                   11 (0 to 77)   1.05 (0.91 to 1.22)   0.45   0 (0 to 79)
  Glu/Glu vs Asp/Asp           1.10 (0.80 to 1.50)   0.59                   0 (0 to 75)    1.10 (0.79 to 1.52)   0.45   0 (0 to 79)
  Glu/Asp vs Asp/Asp           1.11 (0.82 to 1.50)   0.08                   50 (0 to 80)   0.97 (0.76 to 1.24)   0.52   0 (0 to 79)
  Glu/Asp+Glu/Glu vs Asp/Asp   1.14 (0.86 to 1.51)   0.10                   46 (0 to 79)   1.02 (0.80 to 1.29)   0.42   0 (0 to 79)
  Codon 416 (Asian)                                                                                                     
  Glu vs Asp                   1.22 (0.99 to 1.51)   0.47                   0 (0 to 90)    1.12 (0.83 to 1.52)   0.35   0 (NA)
  Glu/Glu vs Asp/Asp           1.30 (0.67 to 2.55)   0.87                   0 (0 to 90)    1.48 (0.61 to 3.60)   0.79   0 (NA)
  Glu/Asp vs Asp/Asp           1.32 (0.84 to 2.05)   0.09                   59 (0 to 88)   1.06 (0.72 to 1.54)   0.29   11 (NA)
  Glu/Asp+Glu/Glu vs Asp/Asp   1.36 (1.04 to 1.78)   0.13                   51 (0 to 86)   1.10 (0.76 to 1.58)   0.29   11 (NA)
  Codon 416 (Caucasian)                                                                                                 
  Glu vs Asp                   1.04 (0.88 to 1.22)   0.27                   24 (0 to 92)   NA                    NA     NA
  Glu/Glu vs Asp/Asp           1.04 (0.73 to 1.49)   0.21                   36 (0 to 80)   NA                    NA     NA
  Glu/Asp vs Asp/Asp           0.91 (0.66 to 1.26)   0.42                   0 (0 to 90)    NA                    NA     NA
  Glu/Asp+Glu/Glu vs Asp/Asp   0.96 (0.70 to 1.31)   0.28                   21 (0 to 92)   NA                    NA     NA

NA, not available; Ph, p value for heterogeneity.

###### 

Pooled ORs and 95% CIs of overall and subgroup meta-analysis, heterogeneity test and sensitivity analysis in the codon 420 polymorphism

  Genetic model                Meta-analysis         Sensitivity analysis                                                
  ---------------------------- --------------------- ---------------------- --------------- --------------------- ------ --------------
  Codon 420 (overall)                                                                                                    
  Lys vs Thr                   1.18 (0.95 to 1.46)   0.05                   56 (0 to 82)    1.11 (0.88 to 1.40)   0.10   49 (0 to 81)
  Lys/Lys vs Thr/Thr           1.11 (0.74 to 1.67)   0.53                   0 (0 to 75)     1.00 (0.65 to 1.54)   0.73   0 (0 to 79)
  Lys/Thr vs Thr/Thr           1.29 (0.95 to 1.76)   0.02                   63 (11 to 85)   1.17 (0.86 to 1.58)   0.08   52 (0 to 82)
  Lys/Thr+Lys/Lys vs Thr/Thr   1.29 (0.94 to 1.76)   0.01                   66 (19 to 86)   1.16 (0.86 to 1.57)   0.07   54 (0 to 83)
  Codon 420 (Asian)                                                                                                      
  Lys vs Thr                   1.49 (1.19 to 1.85)   0.37                   0 (0 to 90)     1.48 (1.07 to 2.05)   0.16   50 (NA)
  Lys/Lys vs Thr/Thr           2.08 (0.76 to 5.69)   0.76                   0 (0 to 90)     1.35 (0.25 to 7.12)   0.74   0 (NA)
  Lys/Thr vs Thr/Thr           1.80 (1.36 to 2.38)   0.35                   5 (0 to 90)     1.67 (1.14 to 2.43)   0.19   42 (NA)
  Lys/Thr+Lys/Lys vs Thr/Thr   1.81 (1.37 to 2.39)   0.31                   14 (0 to 91)    1.67 (1.15 to 2.43)   0.17   47 (NA)
  Codon 420 (Caucasian)                                                                                                  
  Lys vs Thr                   0.98 (0.82 to 1.18)   0.48                   0 (0 to 90)     NA                    NA     NA
  Lys/Lys vs Thr/Thr           0.98 (0.63 to 1.53)   0.40                   0 (0 to 90)     NA                    NA     NA
  Lys/Thr vs Thr/Thr           0.97 (0.76 to 1.25)   0.53                   0 (0 to 90)     NA                    NA     NA
  Lys/Thr+Lys/Lys vs Thr/Thr   0.97 (0.77 to 1.23)   0.52                   0 (0 to 90)     NA                    NA     NA

NA, not available; Ph, p value for heterogeneity.

![Forest plots describing the association of the codon 416 polymorphism with type 2 diabetes mellitus under (A) Glu versus Asp, (B) Glu/Glu versus Asp/Asp, (C) Glu/Asp versus Asp/Asp and (D) Glu/Asp+Glu/Glu versus Asp/Asp models.](bmjopen2014005617f02){#BMJOPEN2014005617F2}

![Forest plots describing the association of the codon 420 polymorphism with type 2 diabetes mellitus under (A) Lys versus Thr, (B) Lys/Lys versus Thr/Thr, (C) Lys/Thr versus Thr/Thr and (D) Lys/Thr+Lys/Lys versus Thr/Thr models.](bmjopen2014005617f03){#BMJOPEN2014005617F3}

Heterogeneity test {#s3c}
------------------

Heterogeneity analyses of the four genetic models were conducted respectively. The results showed that there was significant heterogeneity among the six studies. Then the source of heterogeneity was explored. Studies were stratified by the following characteristics: source of cases, ethnicity and source of controls. Results of meta-regression showed that the systemic results were not affected by these characteristics except for ethnicity (p\<0.05) in the codon 420 polymorphism (shown in [table 2](#BMJOPEN2014005617TB2){ref-type="table"}). In codon 420, under the dominant model, the overall I^2^ is 66% (Ph=0.01), but in the analysis of ethnicity the heterogeneity was significantly removed in Asians (I^2^=14%, Ph=0.31) and in Caucasians (I^2^=0%, Ph=0.52). Similar results were also detected in the allele model. Results are shown in [tables 2](#BMJOPEN2014005617TB2){ref-type="table"}--[4](#BMJOPEN2014005617TB4){ref-type="table"}.

Sensitivity analysis {#s3d}
--------------------

To further strengthen our conclusions, sensitivity analysis was performed by removing the lowest quality of study[@R11] not in HWE. For the overall analysis, the OR and 95% CI were similar with the former OR and 95% CI when the study was omitted. For the Asian subgroup analysis, when the study was omitted, the OR of the dominant model of codon 416, which was significant previously (OR=1.36, 95% CI 1.04 to 1.78), became insignificant (OR=1.10, 95% CI 0.76 to 1.58). Results are presented at [tables 3](#BMJOPEN2014005617TB3){ref-type="table"} and [4](#BMJOPEN2014005617TB4){ref-type="table"}.

Discussion {#s4}
==========

Previous studies have evaluated the association between DBP polymorphisms and the risk of T2DM.[@R11] However, the results remain conflicting and inconsistent, and thus a systematic review and meta-analysis of association between the DBP polymorphisms and T2DM were of great value. Our findings showed that there was no significant association between codon 420 or codon 416 variation of DBP and T2DM in the overall population as well as in the Caucasian population. However, the polymorphisms of codon 416 and codon 420 in DBP were associated with an increased risk of T2DM in Asians.

The association between DBP andT2DM/prediabetes metabolic traits had been reported in a different population. A study conducted on a Japanese population showed an association between DBP genetic variations and insulin resistance.[@R4] Variations in the *DBP* are associated with oral glucose tolerance in non-diabetic Pima Indians.[@R19] Similarly, in Dogrib Indians, the *DBP* genotype had a significant effect on the fasting insulin level.[@R20] A study conducted on the Shanghai population from China also suggested the effect of *DBP* variations on the function of a β cell in a population with abnormal glucose metabolism.[@R21] Significant associations between *DBP* and T2DM were found in the Asian population.[@R11] [@R15] [@R16] In Caucasians, however, similar conclusions were not found.[@R12] So it is possible for us to believe that the effect of variations of *DBP* on the development of T2DM is peculiar to the Asian population, which is identical to the conclusion of our meta-analysis, in which results of the subgroup analysis showed that individuals carrying the Lys allele or Lys/Thr+Lys/Lys, Lys/Thr genotypes had more risk for T2DM in the Asian population. Subgroup analysis also suggested that variations at codon 416 were linked with T2DM risk in Asians. These findings might also suggest that T2DM is a disease with heterogeneity in the *DBP* polymorphisms among populations of different racial, ethnic and geographic backgrounds. In the sensitivity analysis, when the study by Hirai *et al* was excluded, the evident association became insignificant (before OR (95% CI) 1.36 (1.04 to 1.78); after OR (95% CI) 1.10 (0.76 to 1.58)). So this result should be interpreted cautiously in this population.

In the present meta-analysis, there existed a significant heterogeneity among the six studies. The results of the exploration of heterogeneity showed that ethnicity was the characteristic leading to heterogeneity under the dominant model in codon 420. Subgroup analysis by ethnicity also proved the conclusion. Stratified analysis based on age or gender, which may be the source of heterogeneity, was not performed on account of lack of information in these studies.

Currently, the mechanism of the association between the *DBP* polymorphism andT2DM remains unclear. There exist some possible mechanisms. *DBP* variations have an impact on the metabolite of vitamin D, thereby affecting the amount and activity of vitamin D in the β cell which play an important role in insulin secretion. Another possibility is that the association might be not due to the vitamin D metabolite. Fatty acids, as one of the ligands of DBP, may also induce β cell abnormalities when it is at a high level in the pancreas islet.[@R19] As a macrophage-activating factor, *DBP* is also critical to the immune system. Several cytokines, such as the tumour necrosis factor, could play important roles in insulin sensitivity.[@R4] It is also possible that the association of the *DBP* polymorphism with T2DM does not result from functional variations in *DBP*, but is derived from a variation in a closely linked gene on chromosome 4q12.[@R11]

Strengths and limitations {#s4a}
-------------------------

To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate the association of DBP polymorphisms with T2DM. In this meta-analysis, sensitivity analysis and meta-regression were conducted. In addition, several limitations of this study should also be addressed. First, the sample size was relatively small for stratified analyses, which weakened our conclusions. Therefore, more studies need to be conducted to obtain a more reliable result. Second, T2DM is a complex metabolic disorder caused by the interaction of multiple genetic and environmental factors; so gene-gene and gene-environment interactions should also be taken into account to conclude a true effect if possible. Third, detailed information at an individual level was lacking in previous studies, so some stratified analyses were not able to be performed. If individual raw data were available, effect induced by age, gender, medication use and other environmental factors (sun exposure, dietary vitamin D intake, etc.) could also be investigated. Fourth, we are unable to control against publication bias for such a small number of studies. Additionally, results of Genome-wide association study (GWAS) studies were not included because the raw data had not been published.

Conclusions {#s5}
===========

In conclusion, this meta-analysis had pooled all the available data related to the *DBP* polymorphism and T2DM, and indicated that the *DBP* polymorphism was only moderately associated with an increased susceptibility to T2DM in Asians but not in Caucasians. Therefore, more well-designed and large sample studies are warranted to confirm this conclusion, and to fully understand the mechanism of T2DM. Additionally, prospective cohort studies in combination with analyses of other gene and environment factors are also necessary to explore the true effect of the *DBP* polymorphism on the risk of T2DM.
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